Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Laboratorio Farmaceutico Erfo SpA's annulizedROA % for the quarter that ended in Dec. 2025 is
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Laboratorio Farmaceutico Erfo SpA Asset Turnover Related Terms
Laboratorio Farmaceutico Erfo SpA Asset Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:ERFO vs KHC, GIS, HRL: Asset Turnover Comparison
For the Packaged Foods subindustry, Laboratorio Farmaceutico Erfo SpA's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorio Farmaceutico Erfo SpA Asset Turnover vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Laboratorio Farmaceutico Erfo SpA's Asset Turnover distribution charts can be found below:
* The bar in red indicates where Laboratorio Farmaceutico Erfo SpA's Asset Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Laboratorio Farmaceutico Erfo SpA (MIL:ERFO) has a Asset Turnover of 0.38 as of Dec. 2025. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Laboratorio Farmaceutico Erfo SpA and its competitors.
Is Laboratorio Farmaceutico Erfo SpA's Asset Turnover too high?
Laboratorio Farmaceutico Erfo SpA's current Asset Turnover is 0.38. Overall, Laboratorio Farmaceutico Erfo SpA has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorio Farmaceutico Erfo SpA's Asset Turnover compare to KHC and GIS?
Laboratorio Farmaceutico Erfo SpA's Asset Turnover of 0.38 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Consumer Packaged Goods company?
A good Asset Turnover depends on the Consumer Packaged Goods industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Laboratorio Farmaceutico Erfo SpA and its competitors. Laboratorio Farmaceutico Erfo SpA's current Asset Turnover is 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorio Farmaceutico Erfo SpA stock overvalued right now?
Based on GuruFocus' analysis, Laboratorio Farmaceutico Erfo SpA (MIL:ERFO) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.10, compared to a current price of €1.18 — trading 43.8% below its estimated fair value. The current Asset Turnover is 0.38. Laboratorio Farmaceutico Erfo SpA's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Laboratorio Farmaceutico Erfo SpA (MIL:ERFO), the current Asset Turnover is 0.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorio Farmaceutico Erfo SpA (MIL:ERFO) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorio Farmaceutico Erfo SpA stock appears to be undervalued.
The current stock price of €1.18 is trading 43.8% below its estimated GF Value™ of €2.10.
GuruFocus considers Laboratorio Farmaceutico Erfo SpA to be Significantly Undervalued.
Key valuation signals for MIL:ERFO:
Asset Turnover: 0.38
GF Value™: €2.10 vs. price of €1.18 (43.8% below fair value)
No single metric tells the full story. See the MIL:ERFO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorio Farmaceutico Erfo SpA Business Description
Laboratorio Farmaceutico Erfo SpA operates in the nutraceutical sector. The company specializes in formulating and producing food supplements and natural medicines in different forms such as liquids, powders, granules, tablets, and soft gels. Geographically, the company generates a majority of its revenue from Italy followed by Spain, France, Belgium, and other countries.
68GF Score
Get the complete analysis for MIL:ERFO
Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:ERFO has been successfully added to your 
